nach oben

Erschienen in:

01.05.2013 | Original article

Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer

verfasst von: J. Boda-Heggemann, MD, PhD, C. Weiss, PhD, V. Schneider, MSc, R.-D. Hofheinz, MD, S. Haneder, MD, H. Michaely, MD, H. Wertz, U. Ronellenfitsch, MD, A. Hochhaus, MD, F. Wenz, MD, F. Lohr, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In a retrospective analysis, adjuvant intensity-modulated radiation therapy (IMRT) combined with modern chemotherapy improved advanced gastric cancer survival rates compared to a combination of three-dimensional conformal radiation therapy (3D-CRT) and conventional chemotherapy. We report on the long-term outcomes of two consecutive patient cohorts that were treated with either IMRT and intensive chemotherapy, or 3D-CRT and conventional chemotherapy.

Patients and methods

Between 2001 and 2008, 65 consecutive gastric cancer patients received either 3D-CRT (n = 27) or IMRT (n = 38) following tumor resection. Chemotherapy comprised predominantly 5-fluorouracil/folinic acid (5-FU/FA) in the earlier cohort and capecitabine plus oxaliplatin (XELOX) in the latter. The primary endpoints were overall survival (OS) and disease-free survival (DFS).

Results

Median OS times were 18 and 43 months in the 3D-CRT and IMRT groups, respectively (p = 0.0602). Actuarial 5-year OS rates were 26 and 47 %, respectively. Within the IMRT group, XELOX gave better results than 5-FU/FA in terms of OS, but this difference was not statistically significant. The primary cause of death in both groups was distant metastasis. Median DFS times were 14 and 35 months in the 3D-CRT and IMRT groups, respectively (p = 0.0693). Actuarial 5-year DFS rates were 22 and 44 %, respectively. Among patients receiving 5-FU/FA, DFS tended to be better in the IMRT group, but this was not statistically significant. A similar analysis for the XELOX group was not possible as 3D-CRT was almost never used to treat these patients. No late toxicity exceeding grade 3 or secondary tumors were observed.

Conclusion

After a median follow-up period of over 5 years, OS and DFS were improved in the IMRT/XELOX treated patients compared to the 3D-CRT/5-FU/FA group. Long-term observation revealed no clinical indications of therapy-induced secondary tumors or renal toxicity.

Bleiberg H, Goffin JC, Dalesio O et al (1989) Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 15:535–543PubMed

Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef

Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333PubMedCrossRef

Kim S, Lim DH, Lee J et al (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279–1285PubMedCrossRef

Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef

Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721PubMedCrossRef

Hagen P van, Hulshof MC, Lanschot JJ van et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRef

Leibl BJ, Vitz S, Schafer W et al (2011) Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol 187:231–237PubMedCrossRef

Brunner T (2012) Despite of the updated analysis of the SWOG-directed Intergroup Study 0116, adjuvant radiochemotherapy is not yet the standard for gastric cancer after curative resection. Strahlenther Onkol 188(11):1052–1053PubMedCrossRef

10.

Lordick F (2012) Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial. Strahlenther Onkol 188:636–637PubMedCrossRef

11.

Guckenberger M (2012) Indications for neoadjuvant or definitive radiochemotherapy in esophageal cancer of the highest evidence quality. Strahlenther Onkol 188:949–950PubMedCrossRef

12.

Smalley SR, Gunderson L, Tepper J et al (2002) Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 52:283–293PubMedCrossRef

13.

Hofheinz RD, Wenz F, Lukan N et al (2009) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer–an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73:142–147PubMedCrossRef

14.

Boda-Heggemann J, Hofheinz RD, Weiss C et al (2009) Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. Int J Radiat Oncol Biol Phys 75:1187–1195PubMedCrossRef

15.

Jansen EP, Saunders MP, Boot H et al (2007) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67:781–785PubMedCrossRef

16.

Welz S, Hehr T, Kollmannsberger C et al (2007) Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys 69:1429–1435PubMedCrossRef

17.

Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1–11PubMedCrossRef

18.

Lohr F, Dobler B, Mai S et al (2003) Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 179:557–563PubMedCrossRef

19.

Wieland P, Dobler B, Mai S et al (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 59:1236–1244PubMedCrossRef

20.

Hofheinz RD, Wenz F, Lukan N et al (2008) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73(1):142–147PubMedCrossRef

21.

Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRef

22.

Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321PubMedCrossRef

23.

Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856PubMedCrossRef

24.

Buergy D, Lohr F, Baack T et al (2012) Radiotherapy for tumors of the stomach and gastroesophageal junction—a review of its role in multimodal therapy. Radiat Oncol 7:192PubMedCrossRef

25.

Schuhmacher CP, Fink U, Becker K et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918–927PubMedCrossRef

26.

Haneder S, Michaely HJ, Schoenberg SO et al (2012) Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional (1)H-MRI and (23)Na-MRI. Strahlenther Onkol 188:1146–1154PubMedCrossRef

27.

Lee J, Lim do H, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273PubMedCrossRef

Titel: Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer
verfasst von: J. Boda-Heggemann, MD, PhD
C. Weiss, PhD
V. Schneider, MSc
R.-D. Hofheinz, MD
S. Haneder, MD
H. Michaely, MD
H. Wertz
U. Ronellenfitsch, MD
A. Hochhaus, MD
F. Wenz, MD
F. Lohr, MD
Publikationsdatum: 01.05.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0309-2

Springer Medizin

Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer